| 36.70 Data as of May 17 |  +0.38 / +1.05%Today’s Change | 19.03 Today|||52-Week Range 39.00 | +58.39% Year-to-Date |
| SGEN's Adcetris under FDA Review - Analyst Blog May 16 / Zacks.com | Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog May 08 / Zacks.com |
| Previous close | 36.32 |
| Today’s open | 36.44 |
| Day’s range | 35.62 - 36.81 |
| Volume | 418,957 |
| Average volume (3 months) | 804,044 |
| Market cap | $4.5B |
| Dividend yield | -- |
| Earnings growth (last year) | +65.67% |
| Earnings growth (this year) | -78.85% |
| Earnings growth (next 5 years) | +96.00% |
| Revenue growth (last year) | +122.43% |
| P/E ratio | NM |
| Price/Sales | 12.95 |
| Price/Book | 19.43 |
| Today’s change | Today’s % change | |
|---|---|---|
| IDXXIDEXX Laboratories I... | -0.20 | -0.23% |
| ALKSAlkermes Plc | +1.36 | +4.48% |
| WCRXWarner Chilcott Plc | -0.07 | -0.36% |
| THRXTheravance Inc | +0.05 | +0.11% |
| Next reporting date | July 23, 2013 |
| EPS forecast (this quarter) | -$0.19 |
| Annual revenue (last year) | $210.8M |
| Annual profit (last year) | -$53.8M |
| Net profit margin | -25.51% |
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer Clay B. Siegall, PhD |
Chief Operating Officer & Secretary Eric L. Dobmeier |
Corporate headquarters Bothell, Washington |
.
